These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Relapsed Myasthenia Gravis after Nivolumab Treatment.
    Author: Mitsune A, Yanagisawa S, Fukuhara T, Miyauchi E, Morita M, Ono M, Tojo Y, Ichinose M.
    Journal: Intern Med; 2018 Jul 01; 57(13):1893-1897. PubMed ID: 29434145.
    Abstract:
    Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although "new-onset" autoimmune diseases are well-known immune-related adverse events, whether or not nivolumab exacerbates "pre-existing" autoimmune disease remains unclear. We herein report a patient with "pre-existing" myasthenia gravis in whom nivolumab was administered that flared up after the treatment with nivolumab. Regardless of the disease stability, nivolumab has the potential to exacerbate an autoimmune disease, and we must pay close attention to each patient's medical history before administering this agent.
    [Abstract] [Full Text] [Related] [New Search]